Aspects of Antisense Oligodeoxynucleotide, Ribozyme, DNA Enzyme and RNAi Design

Publisher： Bentham Science Publishers

E-ISSN： 1875-6158|4|1|1-15

ISSN： 1568-0150

Source： Current Medicinal Chemistry - Central Nervous System Agents, Vol.4, Iss.1, 2004-03, pp. : 1-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections

By  

Current Cancer Drug Targets, Vol. 1, Iss. 3, 2001-11 ,pp. : 241-247

Bentham Science Publishers

Access to resources Recommend Favorite

Ribozyme: RNA as an enzyme, but as a therapeutic?

By Burke J.F.   Thomas S.M.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1093-1097

Informa Healthcare

Access to resources Recommend Favorite

The Potential Role of Antisense Oligodeoxynucleotide Therapy for Cardiovascular Disease

By Phillips M.I.   Galli S.M.   Mehta J.L.  

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 239-248

Adis International

Access to resources Recommend Favorite

Delivery of Antisense Oligodeoxynucleotide as Inhibitor of 5-Hydroxytryptamine Reuptake*

By Miller K.J.   Chattaraj S.C.   Das S.K.  

Pharmacy and Pharmacology Communications, Vol. 5, Iss. 11, 1999-11 ,pp. : 631-634

Pharmaceutical Press

Access to resources Recommend Favorite

The Design of Vectors for RNAi Delivery System

By  

Current Pharmaceutical Design, Vol. 14, Iss. 13, 2008-05 ,pp. : 1327-1340

Bentham Science Publishers

Access to resources Recommend Favorite